glp-1 anesthesia guidelines 2025 Updated guidance for patients using GLP-1/GIP receptor agonists The 2023 ASA position on

Obes Surg 28:35533558 Bonnet JB et al (2024) Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery

Toward integrated and robust workflows Thinking more broadly, as GLP-1 drugs continue to expand in both therapeutic scope and commercial scale, analytical strategies will need to evolve to keep up with demand and complexity

The difference is cost and accessibility, not therapeutic effectiveness

5 , 209ra151 (2013) J.P

Following liraglutide treatment, the upregulation of microglial cell number and proinflammatory factors was markedly decreased, and microglia exhibited much longer process lengths in the TNC